Astellas Pharma Inc. and Kotobuki Pharmaceutical Co. Ltd. have disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of neurodegeneration and inflammatory disorders.
Kotobuki Pharmaceutical Co. Ltd. and Astellas Pharma Inc. have described NLRP3 inflammasome inhibitors reported to be useful for the treatment of neurodegeneration and inflammatory disorders.
